Celiprolol: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 27: Line 27:


A recent clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular [[Ehlers–Danlos syndrome]].  This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall).<ref>{{cite journal | author = Ong K-T et al. | title = Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial | journal = Lancet | year = 2010 | doi=10.1016/S0140-6736(10)60960-9 | volume = 376 | issue = 9751 | pages = 1476–1484 | pmid = 20825986}}</ref>  
A recent clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular [[Ehlers–Danlos syndrome]].  This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall).<ref>{{cite journal | author = Ong K-T et al. | title = Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial | journal = Lancet | year = 2010 | doi=10.1016/S0140-6736(10)60960-9 | volume = 376 | issue = 9751 | pages = 1476–1484 | pmid = 20825986}}</ref>  
==References==
{{reflist|2}}


==External Links==
==External Links==
Line 38: Line 41:
[[Category:Drug]]
[[Category:Drug]]
[[Category:Beta blockers]]
[[Category:Beta blockers]]
[[Category:Antihypertensive agents]]

Revision as of 02:23, 25 July 2014

Celiprolol
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H33N3O4
Molar mass379.49 g/mol

WikiDoc Resources for Celiprolol

Articles

Most recent articles on Celiprolol

Most cited articles on Celiprolol

Review articles on Celiprolol

Articles on Celiprolol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Celiprolol

Images of Celiprolol

Photos of Celiprolol

Podcasts & MP3s on Celiprolol

Videos on Celiprolol

Evidence Based Medicine

Cochrane Collaboration on Celiprolol

Bandolier on Celiprolol

TRIP on Celiprolol

Clinical Trials

Ongoing Trials on Celiprolol at Clinical Trials.gov

Trial results on Celiprolol

Clinical Trials on Celiprolol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Celiprolol

NICE Guidance on Celiprolol

NHS PRODIGY Guidance

FDA on Celiprolol

CDC on Celiprolol

Books

Books on Celiprolol

News

Celiprolol in the news

Be alerted to news on Celiprolol

News trends on Celiprolol

Commentary

Blogs on Celiprolol

Definitions

Definitions of Celiprolol

Patient Resources / Community

Patient resources on Celiprolol

Discussion groups on Celiprolol

Patient Handouts on Celiprolol

Directions to Hospitals Treating Celiprolol

Risk calculators and risk factors for Celiprolol

Healthcare Provider Resources

Symptoms of Celiprolol

Causes & Risk Factors for Celiprolol

Diagnostic studies for Celiprolol

Treatment of Celiprolol

Continuing Medical Education (CME)

CME Programs on Celiprolol

International

Celiprolol en Espanol

Celiprolol en Francais

Business

Celiprolol in the Marketplace

Patents on Celiprolol

Experimental / Informatics

List of terms related to Celiprolol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Celiprolol (brand names Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm) is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.

A recent clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall).[1]

References

  1. Ong K-T; et al. (2010). "Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial". Lancet. 376 (9751): 1476–1484. doi:10.1016/S0140-6736(10)60960-9. PMID 20825986.

External Links